CN102283859A - Application of dicliptera chinensis polysaccharide - Google Patents
Application of dicliptera chinensis polysaccharide Download PDFInfo
- Publication number
- CN102283859A CN102283859A CN 201110264207 CN201110264207A CN102283859A CN 102283859 A CN102283859 A CN 102283859A CN 201110264207 CN201110264207 CN 201110264207 CN 201110264207 A CN201110264207 A CN 201110264207A CN 102283859 A CN102283859 A CN 102283859A
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- molecular weight
- group
- application
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The invention discloses application of dicliptera chinensis polysaccharide. According to the application, the liver protecting and enzyme reducing activities of polysaccharide with different molecular weights are researched and summarized, particularly including application of a polysaccharide group with the molecular weight of less than 6000 and a total polysaccharide group to preparation of a medicament for treating TP (Total Protein) rise and/or SOD (Superoxide Dismutase) enzymatic activity reduction symptom caused by liver damage or health-care products, application of the polysaccharide group with the molecular weight of less than 6000 and the total polysaccharide group to preparation of a medicament for treating GSH-Px (Glutathione Peroxidase) enzymatic activity reduction symptom caused by liver damage or health-care products, and the like. According to the application disclosed by the invention, the phenomena of complex components and lower content of crude polysaccharides are improved and the relation between the molecular weight composition and the functions of polysaccharide is summarized. The dicliptera chinensis can be applied to preparation of a medicament for protecting liver and reducing enzyme. The product prepared by the invention is easy to dissolve and simultaneously retains the liver protecting physiologically activity of the dicliptera chinensis polysaccharide; and the product has high yield, high content and low preparation cost.
Description
Technical field
The invention belongs to medical technical field, be specifically related to a kind of preparation method and application aspect preparation treatment liver injury medicament thereof of Herba Diclipterae Chinensis polysaccharide.
Background technology
Hepatic injury is the invasion that liver is subjected to extraneous factor, thus the liver damage that causes.Hepatitis virus can cause the damage of liver, but not every hepatic injury must be a hepatitis just.Hepatic injury mainly contains due to the reasons such as violence nature hepatic injury, pathologic hepatic injury, chemical liver injury.Violence nature hepatic injury performance disease is obviously serious fast; Pathologic hepatic injury and chemical liver injury are more common, but pathologic and chemical liver injury development are comparatively slow.
Due to illness the hepatic injury patient that causes of factors such as substance, chemicals or excessive consumption of alcohol is more and more, China at present under the hepatic injury patient exceeded ten million, modern medicine there is no specific drug aspect the treatment of intervening hepatic injury.
In the clinical treatment of hepatic injury, generally adopt the Comprehensive Treatment method, i.e. the common partner treatment of hepatic, antiviral agents and immunostimulant, hepatic focuses on the recovery of liver, antiviral agents, immunostimulant focus on removes intravital virus.Real at present effectively antiviral agents is very few, resembles the anti-hepatic-B virus medicine that lamivudine, famciclovir etc. have just gone on the market in the world, also can't suppress virus fully.The effective immunostimulant of anti-hepatitis virus of generally acknowledging is an interferon at present, but also can't overcome the knock-on problem of virus.Therefore in the treatment technology field of viral hepatitis, the research of antiviral agents, immunostimulant and hepatoprotective is all very important, especially needs hepatic in the treatment of hepatitis A or the damaging hepatitis of poisonous substance, and hepatic market is huge.
Herba Diclipterae Chinensis, Acanthaceae (Acanthaceae) plant Herba Diclipterae Chinensis Dicliptera chinensis (L.) Juss., have heat-clearing and toxic substances removing, removing heat from blood, promote the production of body fluid, the effect of diuresis, be used for hepatic injury, calentura macule, have blood in stool, hematuria, dysuria, toxic swelling furuncle etc., mainly contain organic acid, saccharide, aminoacid ingredient.Have been found that, the Herba Diclipterae Chinensis polysaccharide has hepatoprotective effect, but prior art research report concentrates on the research of Herba Diclipterae Chinensis crude polysaccharides substantially, because Herba Diclipterae Chinensis crude polysaccharides complicated component, content is lower, and the relation between polysaccharide structures and the function it be unclear that, the physiological disposition of polysaccharide, mechanism of action the unknown, difficult quality control causes the drug effect poor repeatability, is difficult to enter the international market.
Summary of the invention
The objective of the invention is to overcome the technical deficiency that existing Herba Diclipterae Chinensis is used, a kind of application of Herba Diclipterae Chinensis different molecular weight polysaccharide is provided.
A kind of preparation method of Herba Diclipterae Chinensis polysaccharide is provided, may further comprise the steps:
(1) will get water extract with water extraction after the defat of Herba Diclipterae Chinensis herb, the remove impurity; Water extract removes protein after precipitate with ethanol obtains the Herba Diclipterae Chinensis total polysaccharides;
The method and the process conditions of described defat are: the method that adopts the defat of organic solvent reflux, extract; Its
Middle organic solvent can be petroleum ether, ether etc., preferred petroleum ether, and consumption is determined (can soak medical material gets final product) according to the medical material volume.
Described remove impurity is that to adopt dehydrated alcohol or volume by volume concentration be 95% ethanol, and the ethanol consumption is preferably according to being to determine at 1: 1 with the medical material volume ratio;
Use water extraction after the defat remove impurity, the Herba Diclipterae Chinensis herb quality of the consumption of water after according to defat, remove impurity: water (volume) is 1g: 5～20mL;
Described water extract removal method of protein and process conditions are with reference to present technique field routine.
Described precipitate with ethanol is that the employing volume by volume concentration is 95% ethanol, and the ethanol consumption is with reference to present technique field routine.
(2) get the Herba Diclipterae Chinensis total polysaccharides that step (1) prepares, use water dissolution, adopt the different molecular weight bag filter that dams, obtain Herba Diclipterae Chinensis different molecular weight polysaccharide group.
Step (2) adopts the Herba Diclipterae Chinensis total polysaccharides: the ratio of 1g: the 1～4mL Herba Diclipterae Chinensis total polysaccharides that is dissolved in water,
Particularly, the present invention is Herba Diclipterae Chinensis plant herb or any part, pulverize, and defat, dehydrated alcohol or volume ratio are that alcohol reflux 1～2h of 95% carries out remove impurity; To extract 2 times with proper amount of boiling water behind the ethanol to the greatest extent through the volatilization of the Herba Diclipterae Chinensis medicinal residues after the remove impurity, each 1～2h, merge extractive liquid,, conventional method is evaporated to the thick paste shape, gets concentrate;
Adopted chloroform-n-butyl alcohol (4: 1, volume ratio) repeatedly extraction (with reference to the Sevage method) removes deproteinize with above-mentioned concentrate, add volume by volume concentration and be 95% ethanol and make the pure content of extract reach 80% (volume ratio content), will contain pure extract and place 4 ℃ of refrigerator precipitate with ethanol 8～12h; Sucking filtration, the filtering residue absolute ethanol washing, 40～60 ℃ of drying 4～6h of filtering residue with after the washing promptly get the Herba Diclipterae Chinensis total polysaccharides;
Get Herba Diclipterae Chinensis total polysaccharides water dissolution, the molecular weight that will dam is that 6000 semipermeable membranes are made bag filter, Herba Diclipterae Chinensis total polysaccharides water-soluble liquid packed into, and to add water in the bag filter an amount of, dialyse for 25 ℃, each 3～6h dialyses 3 times, 3 dialysis solution is merged to concentrate then, adding volume by volume concentration in the concentrate is that 95% ethanol makes the pure content of concentrate reach 80%, will contain pure concentrate and place 4 ℃ of refrigerator precipitate with ethanol 8～12h; Sucking filtration, 40～60 ℃ of drying 4～6h of filtering residue promptly get molecular weight and are lower than 6000 Herba Diclipterae Chinensis polysaccharide;
Be that the residue lysate is transferred to that to adopt the molecular weight that dams be that 10000 semipermeable membrane is made bag filter in 6000 the bag filter with the above-mentioned molecular weight that dams, it is an amount of to add water, dialyse in 25 ℃, each 3～6h, dialyse 3 times, then 3 dialysis solution merging are concentrated, adding volume by volume concentration is that 95% ethanol makes the pure content of concentrate reach 80%, places 4 ℃ of refrigerator precipitate with ethanol 8～12h; Sucking filtration, 40～60 ℃ of drying 4～6h of filtering residue, promptly get molecular weight greater than 6000 less than 10000 Herba Diclipterae Chinensis polysaccharide;
With the above-mentioned molecular weight that dams be in 10000 the bag filter residue lysate to be transferred to the molecular weight that dams be that 10000 semipermeable membranes are made bag filter, it is an amount of to add water, dialyse in 25 ℃, each 3～6h, dialyse 3 times, the molecular weight that will dam be in 10000 the bag filter remaining lysate to add volume by volume concentration be that 95% ethanol makes pure content reach 80%, place 4 ℃ of refrigerator precipitate with ethanol 8～12h; Sucking filtration, 40～60 ℃ of drying 4～6h of filtering residue promptly get molecular weight and are higher than 10000 Herba Diclipterae Chinensis polysaccharide.
Technique scheme of the present invention prepares the Herba Diclipterae Chinensis polysaccharide of different molecular weight respectively.
The invention provides Herba Diclipterae Chinensis different molecular weight polysaccharide group and have application well aspect the preparation treatment liver injury medicament.
The Herba Diclipterae Chinensis polysaccharide molecular weight that the present invention prepares can be applied to prepare prevention or alleviate the diseases related medicine aspect of active oxygen less than 6000 polysaccharide groups, molecular weight 6000～10000 polysaccharide groups, have antioxidant activity greater than 10000 polysaccharide groups;
Each polysaccharide administration group rat blood serum ALT, AST is active relatively to have significant difference (P＜0.01) with model control group, and wherein molecular weight is remarkable greater than 10000 groups of effects less than 6000 groups, molecular weight;
Molecular weight can significantly reduce because the TP that hepatic injury causes raises (P＜0.05) less than 6000 polysaccharide groups and total polysaccharides group; Total polysaccharides group and molecular weight can significantly strengthen less than 6000 polysaccharide groups because the SOD enzymatic activity that hepatic injury causes reduces (P＜0.05);
Total polysaccharides group and molecular weight 6000～10000 polysaccharide groups significantly strengthen because the GSH-Px enzymatic activity that hepatic injury causes reduces (P＜0.01); Each polysaccharide administration group liver tissues of rats MDA content and the apparent in view reduction of model control group (P＜0.01), wherein total polysaccharides group, molecular weight are remarkable greater than 10000 groups of effects with molecular weight less than 6000 groups.
Research summary of the present invention obtains, and the Herba Diclipterae Chinensis polysaccharide can reduce CCl
4Due to acute liver damage, wherein, for the liver index, molecular weight is greater than 10000 groups of effect optimums (P＜0.05); For index and spleen index, total polysaccharides group effect optimum, but there was no significant difference; For the kidney index, each administration group does not all have significant difference.Herba Diclipterae Chinensis different molecular weight polysaccharide group can be applicable to prepare the medicine aspect for the treatment of hepatic injury.
It is known in the art that the purpose method for compositions is made in Herba Diclipterae Chinensis different molecular weight polysaccharide of the present invention assembly.According to different needs, art book personnel can select suitable additive, compound method, dosage form, unit dose etc. under the present invention.
When the present composition is pharmaceutical composition, can contain suitable pharmaceutical excipient, carrier or diluent etc.Can adopt the pharmaceutical field technique known to carry out preparation.
Pharmaceutical composition of the present invention can adopt multiple dosage form, and this often depends on route of administration.For example, different molecular weight Herba Diclipterae Chinensis polysaccharide of the present invention can be used for preparing the medicine for the treatment of hepatic injury, comprises the preparation that oral medicine and parenteral are used, as injection.
The invention has the beneficial effects as follows:
The present invention overcomes the thinking inertia and the technical limitation of the existing research in present technique field, through long-term a large amount of experimental summary and analyses, adopt simple method, adopt by different molecular weight polysaccharide component as object of study breakthroughly, compare with crude polysaccharides, crude polysaccharides complicated component, phenomenon that content is lower have been improved, summed up the relation between polysaccharide molecular weight composition and the function, help further studying physiological disposition, the mechanism of action of polysaccharide, be convenient to the polysaccharide quality is controlled, improve the drug effect repeatability and the quality stability of Herba Diclipterae Chinensis polysaccharide medicine.Products obtained therefrom of the present invention is easy to dissolving, has kept the physiologically active that protects the liver of Herba Diclipterae Chinensis polysaccharide simultaneously, can more be widely used in the production of medicine, health product or beverage etc.
The present invention adopts membrane separation technique, significantly simplifies preparation technology, and step is simple, and raw material is easy to get, and reduces preparation cost.
Description of drawings
Fig. 1 molecular weight changes less than 6000 polysaccharide groups experiment hepatic pathology, H.E. dyeing, * 400
Fig. 2 molecular weight changes greater than 10000 polysaccharide groups experiment hepatic pathology, H.E. dyeing, * 400
Fig. 3 bifendate group experiment hepatic pathology changes, H.E. dyeing, * 400
The blank group experiment of Fig. 4 hepatic pathology changes H.E. dyeing, * 400
Fig. 5 Herba Diclipterae Chinensis total polysaccharides dialysis operation chart.
The specific embodiment
Further describe the present invention below in conjunction with the drawings and specific embodiments.Unless stated otherwise, reagent that the embodiment of the invention adopts and material are conventional commercial, and the method for employing is present technique field conventional method.
Embodiment 1
Take by weighing exsiccant Herba Diclipterae Chinensis herb coarse powder 1kg, add an amount of defat with petroleum ether, dehydrated alcohol remove impurity, each reflux, extract, 2 hours.Medicinal residues are waved behind the most ethanol boiling water extraction 2 times, each 2 hours, merge extractive liquid,, be concentrated into 800mL, chloroform-n-butyl alcohol (4: 1, volume ratio) repeatedly extracts (with reference to the Sevage method), removes deproteinize, add volume by volume concentration and be 95% ethanol and make pure content reach 80% (volume by volume concentration), precipitate with ethanol is 12 hours in 4 ℃ of refrigerators.Sucking filtration, the filtering residue absolute ethanol washing, and, promptly get the Herba Diclipterae Chinensis total polysaccharides, yield about 9% through 50 ℃ of vacuum dryings 4 hours.
Get Herba Diclipterae Chinensis total polysaccharides 70g, dissolve with the 150mL purified water, the molecular weight that will dam is that 6000 semipermeable membranes are made bag filter, lysate packed into to be added the 1000mL purified water in the bag filter and dialyses for 25 ℃, each 3 hours, dialyses 3 times, then three dialysis solution are merged and be concentrated into 300mL, add 95% (volume by volume concentration, down together) ethanol and make pure content reach 80%, precipitate with ethanol 12h in 4 ℃ of refrigerators.Sucking filtration, filtering residue promptly get molecular weight and are lower than 6000 Herba Diclipterae Chinensis polysaccharide through 50 ℃ of vacuum drying 4h, and yield is 48% of a total polysaccharides quality.
It is that 10000 semipermeable membranes are made bag filter that residue lysate in the bag filter is transferred to the molecular weight that dams, adding the 1000mL purified water dialyses for 25 ℃, each 3h, dialyse 3 times, then three dialysis solution are merged and be concentrated into 300mL, add 95% ethanol and make pure content reach 80%, precipitate with ethanol 12h in 4 ℃ of refrigerators.Sucking filtration, filtering residue be through 50 ℃ of vacuum drying 4h, promptly gets molecular weight and be higher than 6000 and be lower than 10000 Herba Diclipterae Chinensis polysaccharide, and yield is 15% of a total polysaccharides quality.
The molecular weight that will dam is that remaining lysate adds 95% ethanol and makes pure content reach 80% in 10000 the bag filter, precipitate with ethanol 12h in 4 ℃ of refrigerators.Sucking filtration, filtering residue promptly get molecular weight and are higher than 10000 Herba Diclipterae Chinensis polysaccharide through 50 ℃ of vacuum drying 4h, and yield is 34% of a total polysaccharides quality.
The application experiment of embodiment 2 Herba Diclipterae Chinensis different molecular weight polysaccharide groups of the present invention
Male SD rat (220 ± 20g), provide (the quality certification number: SCXK Guangdong 2008-0002) by Guangdong Province's Experimental Animal Center.Rat is divided into 7 groups (10 every group) at random, keeps 12 hours circadian rhythms, and controlled humidity and circulation of air are freely drunk water and ingested, experiment prospective adaptation raising 7d.
Get 70 male SD rats, be divided into 7 groups at random, every group 10, be respectively normal control group, liver injury model group, bifendate group, Herba Diclipterae Chinensis total polysaccharides group, molecular weight less than 6000 Herba Diclipterae Chinensis polysaccharide groups, molecular weight 6000～10000 Herba Diclipterae Chinensis polysaccharide groups and molecular weight greater than 10000 Herba Diclipterae Chinensis polysaccharide groups.Normal control group and model group are irritated stomach and give water for injection every days, and the animal every day that is subjected to reagent and positive controls is according to the dosage gastric infusion, dosage: biphenyl three esters: 150mg/kg; Molecular weight＜6000 group: 500mg/kg; 6000～10000 groups of molecular weight: 150mg/kg; Molecular weight＞10000 group: 300mg/kg.At the 7th day of administration, except that the normal control group, all the other each treated animals were all irritated stomach 0.1%CCl
4Oleum Arachidis hypogaeae semen (0.01mL/g), water 16h is can't help in fasting, abdominal aortic blood behind whole rat anesthesias, 3000 leave heart 15min, isolate serum, and-20 ℃ are saved to analysis ALT, AST, TP biochemical indicator.The blood sampling back is taken out liver, kidney, spleen rapidly, delete blood as much as possible immediately with ice-cold saline, weigh, calculate absolute and relative organ index (organ index=organ weights/body weight (mg/g)), and on same lobules of liver, get 1.00g liver tissue homogenate, centrifugal, get supernatant ,-20 ℃ are saved to analysis.Get simultaneously and get a fritter on the same lobules of liver and do the pathological tissue inspection.Experimental result is shown in Table 1:
Table 1 Herba Diclipterae Chinensis polysaccharide is to the influence (n=10) of Serum ALT, AST and TP level
The p value: a p＜0.01, model group compares with blank group;
B p＜0.05, model group compares with blank group;
C p＜0.01, model group and positive drug and administration group are relatively;
D p＜0.05, model group and positive drug and administration group are relatively;
E p＜0.01, each organizes the polysaccharide group and the positive drug group compares;
F p＜0.05 respectively organizes the polysaccharide group and the positive drug group compares
Experimental result shown in the table 1 shows that liver injury model group and blank group comparing difference are remarkable, and the success of this experimental model is described.Compare with model group, positive controls is obvious suppression ALT, AST activity (P＜0.01) very, significantly reduces because the TP that hepatic injury causes raises (P＜0.05).Active and the apparent in view reduction of model control group of each polysaccharide administration group rat blood serum ALT, AST, comparing all has significant difference (P＜0.01), illustrate that each position of Herba Diclipterae Chinensis polysaccharide all can suppress Rats with Acute Liver Injury serum alt due to the carbon tetrachloride, the active rising of AST, molecular weight＜6000 polysaccharide group most pronounced effects wherein, its effect is near the positive drug bifendate drop pill, and is more effective than total polysaccharides.
Each group is not quite similar for the influence of hepatic injury rat blood serum total protein TP.Wherein molecular weight＜6000 polysaccharide groups and total polysaccharides group can significantly reduce because the TP that hepatic injury causes raises, and molecular weight＜6000 polysaccharide group effects (P＜0.01) are better than total polysaccharides group (P＜0.05) and positive drug group (P＜0.05).Though effect is not remarkable, molecular weight 6000～10000 polysaccharide groups and molecular weight＞10000 polysaccharide groups also can reduce because the TP that hepatic injury causes raises.
The application experiment of embodiment 3 Herba Diclipterae Chinensis different molecular weight polysaccharide groups of the present invention
Experimental technique is with embodiment 2.Experimental result is shown in Table 2:
Each position of table 2 Herba Diclipterae Chinensis polysaccharide is to the influence (n=10) of hepatic tissue enzyme
P value: with embodiment 2.
Experimental result shown in the table 2 shows that liver injury model group and blank group comparing difference are remarkable, the success of illustrative experiment model.Compare with model group, positive control drug significantly strengthens owing to the SOD that hepatic injury causes, GSH-Px enzymatic activity reduce (P＜0.01).
For the SOD enzymatic activity, the total polysaccharides group significantly strengthens because the SOD enzymatic activity that hepatic injury causes reduces (P＜0.01), and effect is better than positive drug bifendate drop pill group; Molecular weight＜6000 polysaccharide groups also can significantly strengthen because the SOD enzymatic activity that hepatic injury causes reduces (P＜0.05), but its effect is not as good as positive drug group and total polysaccharides group.Molecular weight 6000～10000 polysaccharide groups and molecular weight＞10000 polysaccharide group effects and model group be there was no significant difference more then.
For the GSH-Px enzymatic activity, total polysaccharides group and molecular weight 6000～10000 polysaccharide groups significantly strengthen because the GSH-Px enzymatic activity that hepatic injury causes reduces (P＜0.01), the effect positive drug bifendate drop pill group that can match in excellence or beauty.Molecular weight is not remarkable to this enzymatic activity influence less than 6000 polysaccharide groups and molecular weight＞10000 polysaccharide groups.Compare with model group, positive control drug is obvious suppression MDA activity (P＜0.01) very.MDA content and the apparent in view reduction of model control group in each polysaccharide administration group liver tissues of rats, comparing all has significant difference, wherein total polysaccharides group, molecular weight＜6000 polysaccharide groups and molecular weight＞10000 polysaccharide group effects are better than positive drug bifendate drop pill group, total polysaccharides group effect optimum (P＜0.01).
The application experiment of embodiment 4 Herba Diclipterae Chinensis different molecular weight polysaccharide groups of the present invention
Experimental technique is with embodiment 2.Experimental result is seen (H.E. dyeing, original amplification is 400) shown in the accompanying drawing 1～4:
Find CCl through the histopathology check
4Caused the major injury of liver.It is destroyed mainly to show as the liver normal configuration, liver rope arrangement disorder around sinus hepaticus and the central vein congestion, central vein, and hepatic cell fattydegeneration and necrosis, and the periangiitis sexual cell soaks into.So show CCl
4Liver injury model modeling success.The Herba Diclipterae Chinensis polysaccharide is to CCl
4The hepar damnification that causes has improvement effect in various degree.Mainly show the recovery of liver normal configuration, liver rope marshalling, hepatocellular degeneration and downright bad phenomenon reduce, and inflammatory cell infiltration also alleviates.Different molecular weight Herba Diclipterae Chinensis polysaccharide is to CCl
4The hepatic injury improvement effect that causes is difference to some extent.And bifendate is to CCl
4The protective effect of the hepatic injury that causes is atomic.Different molecular weight Herba Diclipterae Chinensis polysaccharide and bifendate are to CCl
4The liver injury protection effect that causes is followed successively by blank group＞molecular weight 6000 following polysaccharide group 〉=molecular weight 6000～10000 polysaccharide groups＞total polysaccharides group 〉=molecular weight 10000 above polysaccharide group＞bifendate group＞model group from effective to difference.
Claims (5)
1. the application of Herba Diclipterae Chinensis polysaccharide aspect preparation treatment hepatic is characterized in that it being molecular weight to be applied to prepare TP that hepatic injury causes raises and/or the medicine or the health product aspect of SOD enzymatic activity reduction disease less than 6000 polysaccharide groups and total polysaccharides group.
2. the Herba Diclipterae Chinensis polysaccharide is in the application of preparation aspect the hepatic, it is characterized in that it being medicine or the health product aspect that molecular weight 6000～10000 polysaccharide groups and total polysaccharides group is applied to prepare the GSH-Px enzymatic activity reduction disease that hepatic injury causes.
3. the application of Herba Diclipterae Chinensis polysaccharide aspect the preparation hepatic is characterized in that it being total polysaccharides group, molecular weight to be applied to preparation with molecular weight greater than 10000 groups of molecular weight, 6000～10000 polysaccharide groups less than 6000 groups suppress active medicine of MDA or health product aspect.
4. the application of Herba Diclipterae Chinensis polysaccharide aspect the preparation hepatic is characterized in that being applied to preparation treatment CCl
4Due to acute liver damage medicine aspect.
5. the Herba Diclipterae Chinensis polysaccharide is in prevention or alleviate application aspect the diseases related medicine of active oxygen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110264207 CN102283859B (en) | 2011-09-07 | 2011-09-07 | Application of dicliptera chinensis polysaccharide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110264207 CN102283859B (en) | 2011-09-07 | 2011-09-07 | Application of dicliptera chinensis polysaccharide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102283859A true CN102283859A (en) | 2011-12-21 |
| CN102283859B CN102283859B (en) | 2013-04-24 |
Family
ID=45330796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110264207 Expired - Fee Related CN102283859B (en) | 2011-09-07 | 2011-09-07 | Application of dicliptera chinensis polysaccharide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102283859B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102600307A (en) * | 2012-03-16 | 2012-07-25 | 蒋勇 | Topical Chinese medicinal composition for treating Weil's disease |
| CN104083393A (en) * | 2014-04-01 | 2014-10-08 | 桂林医学院 | Application of dicliptera chinensis polysaccharide in preparation of medicines for treating liver injury caused by antituberculosis drugs |
| CN106265717A (en) * | 2016-07-21 | 2017-01-04 | 桂林医学院 | Dicliptera chinensis polysaccharide application in preparation preventing and treating diabetes medicament or health product |
| CN107281213A (en) * | 2017-06-30 | 2017-10-24 | 广西医科大学 | A kind of dicliptera chinensis polysaccharide prepares the application in radioactivity dry disease drug |
-
2011
- 2011-09-07 CN CN 201110264207 patent/CN102283859B/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| 《中药材》 20060831 李海燕，王旭深 狗肝菜多糖保肝作用研究 833-834 1-5 第29卷, 第8期 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102600307A (en) * | 2012-03-16 | 2012-07-25 | 蒋勇 | Topical Chinese medicinal composition for treating Weil's disease |
| CN102600307B (en) * | 2012-03-16 | 2014-07-23 | 蒋勇 | Topical Chinese medicinal composition for treating Weil's disease |
| CN104083393A (en) * | 2014-04-01 | 2014-10-08 | 桂林医学院 | Application of dicliptera chinensis polysaccharide in preparation of medicines for treating liver injury caused by antituberculosis drugs |
| CN106265717A (en) * | 2016-07-21 | 2017-01-04 | 桂林医学院 | Dicliptera chinensis polysaccharide application in preparation preventing and treating diabetes medicament or health product |
| CN106265717B (en) * | 2016-07-21 | 2018-10-19 | 桂林医学院 | Application of the dicliptera chinensis polysaccharide in preparing prevention diabetes medicament or health products |
| CN107281213A (en) * | 2017-06-30 | 2017-10-24 | 广西医科大学 | A kind of dicliptera chinensis polysaccharide prepares the application in radioactivity dry disease drug |
| CN107281213B (en) * | 2017-06-30 | 2020-06-16 | 广西医科大学 | Application of kohlrabi polysaccharide in preparation of radioactive xerostomia medicines |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102283859B (en) | 2013-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102283859B (en) | Application of dicliptera chinensis polysaccharide | |
| CN104224885A (en) | Traditional Chinese medicine composition for relieving physical fatigue | |
| CN102210737A (en) | Sweet potato leaf extract and preparation method and use thereof | |
| CN103919854A (en) | Application of butterflybush flower and extract thereof to preparation of medicament | |
| CN104523742B (en) | A kind of polysaccharide composition and its application with protect liver and raising immunization | |
| CN102743424A (en) | Flos chrysanthemi indici effective ingredient and application thereof | |
| CN107412254A (en) | The application of anoectochilus roxburghii polyose extract | |
| CN105111323B (en) | A kind of method for extraction and purification of the black nightshade refined polysaccharide with antitumor activity | |
| CN104758309B (en) | The purposes of raspberry polysaccharide for reducing blood sugar | |
| CN103405501B (en) | Preparation method of three-component blood-activating and stasis-dissolving capsules | |
| CN102988461B (en) | A kind of gadol injection and preparation method thereof | |
| CN104286859B (en) | A kind of for health food improving chemical damage and preparation method thereof | |
| CN101559166B (en) | Ophiopogon japonicus extract, preparation method and hypoglycemic application thereof | |
| CN108186801A (en) | A kind of lentinan health care oral liquid and preparation method thereof | |
| CN1919875A (en) | Cryptoporus volvatus polysaccharide, preparation and application thereof | |
| CN104804107B (en) | A kind of Semen Herpetospermi extraction method of polysaccharides, Semen Herpetospermi polyoses extract and purposes that the extracting method is obtained | |
| CN107056959A (en) | Jerusalem artichoke moderate resistance HSV 1, the composition of RSV, EV 71 and preparation | |
| CN101711790A (en) | Wild Juglans mandshurica bark water extract used for curing liver cancer | |
| CN102389449B (en) | Erigeron breviscapus extract and preparation method and application thereof | |
| CN104258034A (en) | Traditional Chinese medicine composition for boosting immunity | |
| CN103211864B (en) | Melastoma dodecandrum Lour extract product and application of Melastoma dodecandrum Lour in preparation of medicines for treating AIDS | |
| WO2019014037A1 (en) | Method for treating alcoholic hepatitis | |
| CN107213254A (en) | Purposes of the Compound Xueshuantong preparation in the treatment disease mediated medicines of PAF are prepared | |
| CN108245538A (en) | A kind of ginkgo biloba p.e and its medical usage | |
| CN1430966A (en) | Medicine combination contg. effective part of astragalus root |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130424 Termination date: 20140907 |
|
| EXPY | Termination of patent right or utility model |